COVID-19's logistical impact on advanced therapies
Interviewee/Contributor
Matthew Lakelin
Organisation
TrakCel Ltd
Gene therapy
Solving the viral vector bottleneck during a pandemic
Interviewee/Contributor
Géraldine Guérin-Peyrou
Organisation
Polyplus-transfection SA
The changing landscape for haemophilia treatment
Interviewee/Contributor
Victoria English
Organisation
MedNous
Meeting the challenge of viral vector manufacture
Interviewee/Contributor
Gabriel Festoc
Organisation
Polyplus-Transfection SA
Human gene therapy - immunogenicity perspective
Interviewee/Contributor
J Fraser Wright
Organisation
Stanford University School of Medicine
A bioethical framework for therapeutic gene editing
Interviewee/Contributor
Janet Lambert
Organisation
Alliance for Regenerative Medicine
The precedents set by Zolgensma
Interviewee/Contributor
Victoria English
Organisation
MedNous
Advanced therapy financing events in Q1 2019
Interviewee/Contributor
Victoria English
Organisation
MedNous
Microsoft pioneers biological computing
Interviewee/Contributor
Victoria English
Organisation
MedNous
Will gene editing unmask synthetic lethal targets?
Interviewee/Contributor
Ceri Wiggins and Jon Moore
Organisation
Horizon Discovery Group Plc